Organon & Co. (NYSE:OGN), a prominent player in the healthcare sector, has been garnering attention from analysts due to its diverse product portfolio and strategic market positioning. The company ...

SAN DIEGO, May 23, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that the Organon class action lawsuit – captioned Hauser v. Organon & Co., No. 25-cv-05322 (D.N.J.) – seeks ...

Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Organon & Co. (NYSE: OGN) securities between October 31, 2024 and April ...

Law Offices of Howard G. Smith announces an investigation on behalf of Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) investors concerning the Company’s possible violations of ...

On Thursday, BNP Paribas (OTC: BNPQY) Exane adjusted its outlook on Organon & Co. (NYSE: OGN), reducing the price target to $16 from the previous $29, while retaining an Outperform rating on the ...

Organon (OGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Notably, defendants concealed the high priority of Organon's debt reduction strategy following the Company's acquisition of Dermavant, resulting in a 70% decrease for the regular quarterly dividend.

Access our full analysis report here, it’s free. Branded Pharmaceuticals company Organon (NYSE:OGN) jumped 5.8%. Is now the time to buy Organon? Access our full analysis report here, it’s free.

PHILADELPHIA, May 30, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Organon & Co. (“Organon” or the “Company ...

SAN DIEGO, May 23, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Organon & Co. (NYSE: OGN ...